CIRM doesn't want an active scientist president

Shortly after posting my linkurl:news story;http://www.the-scientist.com/news/home/53480/ on incoming linkurl:California Institute for Regenerative Medicine;http://www.the-scientist.com/article/display/22768/ interim president Richard Murphy, Robert Klein--chairman of CIRM's governing board--told me that a policy regarding candidates for the permanent position has recently been enacted. Klein said that through discussions in June and July, the board confirmed a policy that precluded candidates

By | August 10, 2007

Shortly after posting my linkurl:news story;http://www.the-scientist.com/news/home/53480/ on incoming linkurl:California Institute for Regenerative Medicine;http://www.the-scientist.com/article/display/22768/ interim president Richard Murphy, Robert Klein--chairman of CIRM's governing board--told me that a policy regarding candidates for the permanent position has recently been enacted. Klein said that through discussions in June and July, the board confirmed a policy that precluded candidates who wish to maintain active labs during their term as CIRM president. Previously, such candidates were considered for the permanent position. "The most important issue is making certain we're maintaining the highest standard of objective scientific judgment without bias," Klein said. Klein explained that the policy avoids potential conflicts of interest that might arise with a president who also maintains a California-based lab that would be competing for linkurl:CIRM funding;http://www.the-scientist.com/blog/display/52856/ . Additionally, Klein said that the board wants a president who will be able to devote his or her complete attention to the job. "We're looking for this individual to be a leader of stem cell strategy in California, in the nation, and globally," he said. "In order to reach that level of leadership, it's a full-time job."

Popular Now

  1. How Plants Evolved Different Ways to Make Caffeine
  2. Thomson Reuters Predicts Nobelists
    The Nutshell Thomson Reuters Predicts Nobelists

    According to citation statistics, researchers behind programmed cell death pathways and CRISPR/Cas9 are among those in line for Nobel Prizes this year.

  3. Sequencing Reveals Genomic Diversity of the Human Brain
  4. Reviewing Results-Free Manuscripts
    The Nutshell Reviewing Results-Free Manuscripts

    An open-access journal is trialing a peer-review process in which reviewers do not have access to the results or discussion sections of submitted papers.

RayBiotech